125 related articles for article (PubMed ID: 8947909)
1. Encapsulated xenogeneic cells: delivering CNTF to motor neurons.
O'Brien C
Mol Med Today; 1996 Nov; 2(11):448-9. PubMed ID: 8947909
[No Abstract] [Full Text] [Related]
2. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients.
Aebischer P; Schluep M; Déglon N; Joseph JM; Hirt L; Heyd B; Goddard M; Hammang JP; Zurn AD; Kato AC; Regli F; Baetge EE
Nat Med; 1996 Jun; 2(6):696-9. PubMed ID: 8640564
[TBL] [Abstract][Full Text] [Related]
3. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group.
Neurology; 1996 May; 46(5):1244-9. PubMed ID: 8628460
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group.
Clin Neuropharmacol; 1995 Dec; 18(6):515-32. PubMed ID: 8681312
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF.
Aebischer P; Pochon NA; Heyd B; Deglon N; Joseph JM; Zurn AD; Baetge EE; Hammang JP; Goddard M; Lysaght M; Kaplan F; Kato AC; Schluep M; Hirt L; Regli F; Porchet F; De Tribolet N
Hum Gene Ther; 1996 May; 7(7):851-60. PubMed ID: 8860837
[TBL] [Abstract][Full Text] [Related]
6. Treatment of amyotrophic lateral sclerosis using a gene therapy approach.
Aebischer P; Kato AC
Eur Neurol; 1995; 35(2):65-8. PubMed ID: 7796839
[TBL] [Abstract][Full Text] [Related]
7. [Neurotrophic factor treatment in amyotrophic lateral sclerosis].
Tsuzaka K; Mitsumoto H
No To Shinkei; 1998 Jul; 50(7):625-30. PubMed ID: 9739520
[No Abstract] [Full Text] [Related]
8. Will ciliary neurotrophic factor slow progression of motor neuron disease?
Longo FM
Ann Neurol; 1994 Aug; 36(2):125-7. PubMed ID: 8053646
[No Abstract] [Full Text] [Related]
9. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial).
Penn RD; Kroin JS; York MM; Cedarbaum JM
Neurosurgery; 1997 Jan; 40(1):94-9; discussion 99-100. PubMed ID: 8971830
[TBL] [Abstract][Full Text] [Related]
10. Herpes labialis associated with recombinant human ciliary neurotrophic factor.
Kriesel JD; Araneo B; Petajan JP; Spruance SL; Stromatt S
J Infect Dis; 1994 Oct; 170(4):1046. PubMed ID: 7930707
[No Abstract] [Full Text] [Related]
11. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis.
Miller RG; Bryan WW; Dietz MA; Munsat TL; Petajan JH; Smith SA; Goodpasture JC
Neurology; 1996 Nov; 47(5):1329-31. PubMed ID: 8909453
[TBL] [Abstract][Full Text] [Related]
12. Motor unit number estimates and quantitative muscle strength measurements of distal muscles in patients with amyotrophic lateral sclerosis.
Armon C; Brandstater ME; Peterson GW
Muscle Nerve; 1997 Apr; 20(4):499-501. PubMed ID: 9121509
[No Abstract] [Full Text] [Related]
13. Expression of ciliary neurotrophic factor is maintained in spinal motor neurons of amyotrophic lateral sclerosis.
Schorr M; Zhou L; Schwechheimer K
J Neurol Sci; 1996 Sep; 140(1-2):117-22. PubMed ID: 8866436
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.
Miller RG; Petajan JH; Bryan WW; Armon C; Barohn RJ; Goodpasture JC; Hoagland RJ; Parry GJ; Ross MA; Stromatt SC
Ann Neurol; 1996 Feb; 39(2):256-60. PubMed ID: 8967757
[TBL] [Abstract][Full Text] [Related]
15. Lay-offs follow suspension of clinical trials of protein.
Verrall M
Nature; 1994 Jul; 370(6484):6. PubMed ID: 8015607
[No Abstract] [Full Text] [Related]
16. [Deficiency of human ciliary neurotropic factor (CNTF) is not causally related to amyotrophic lateral sclerosis (ALS)].
Takahashi R
Rinsho Shinkeigaku; 1995 Dec; 35(12):1543-5. PubMed ID: 8752458
[TBL] [Abstract][Full Text] [Related]
17. Investigation of a null mutation of the CNTF gene in familial amyotrophic lateral sclerosis.
Orrell RW; King AW; Lane RJ; de Belleroche JS
J Neurol Sci; 1995 Oct; 132(2):126-8. PubMed ID: 8543936
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells.
Zurn AD; Henry H; Schluep M; Aubert V; Winkel L; Eilers B; Bachmann C; Aebischer P
Cell Transplant; 2000; 9(4):471-84. PubMed ID: 11038064
[TBL] [Abstract][Full Text] [Related]
19. Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse.
Sagot Y; Tan SA; Baetge E; Schmalbruch H; Kato AC; Aebischer P
Eur J Neurosci; 1995 Jun; 7(6):1313-22. PubMed ID: 7582105
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of subcutaneously administered recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis: relation to parameters of the acute-phase response. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group.
Clin Neuropharmacol; 1995 Dec; 18(6):500-14. PubMed ID: 8681311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
